Development of a Novel Recombinant Full-Length IgY Monoclonal Antibody against Human Thymidine Kinase 1 for Automatic Chemiluminescence Analysis on a Sandwich Biotin-Streptavidin Platform for Early Tumour Discovery

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/jir/volume-2023/7612566/figures/7612566.fig.002a.svgz" name="7612566.fig.002a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>ECL dot blot assay</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/jir/volume-2023/7612566/figures/7612566.fig.002b.svgz" name="7612566.fig.002b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Auto. chem. analyser</td></tr></table>

<div>Schematic diagram of the two-assay system using hTK1-IgY-rmAb. The detection of STK1p using hTK1-IgY-rmAb on the semiautomatic ECL dot blot assay with BSA platform (a) and the novel automatic chemiluminescence analyser with sandwich-BSA platform (b). M.B.: magnetic bead.</div>

Journal of Immunology Research

fig2

Figure 2

Figure 2: Development of a Novel Recombinant Full-Length IgY Monoclonal Antibody against Human Thymidine Kinase 1 for Automatic Chemiluminescence Analysis on a Sandwich Biotin-Streptavidin Platform for Early Tumour Discovery 

Figure 2 | Development of a Novel Recombinant Full-Length IgY Monoclonal Antibody against Human Thymidine Kinase 1 for Automatic Chemiluminescence Analysis on a Sandwich Biotin-Streptavidin Platform for Early Tumour Discovery 